Filtered By:
Vaccination: Cancer Vaccines

This page shows you your search results in order of date. This is page number 2.

Order by Relevance | Date

Total 104 results found since Jan 2013.

Targeting K-Ras Mutations Show Promise Towards Ending Ras's "Undruggable" Era
Protein Pept Lett. 2022 Oct 3. doi: 10.2174/0929866529666221003124202. Online ahead of print.ABSTRACTIt has almost been 40 years since the Ras proteins were discovered as the first human oncogenes. They remain among the most important genes for regulating mammalian cell growth and are involved in more than a quarter of human cancers. Out of 167 members of the Ras superfamily, K-Ras mutations are the most abundant in human cancers. Particularly, the K-Ras G12C mutations are known to be involved in pancreatic, colon and lung cancers as well as leukemias. Though progress has been made, approaches that target Ras proteins for ...
Source: Protein and Peptide Letters - October 6, 2022 Category: Biochemistry Authors: Paul D Adams D Jamali Muhoza Source Type: research

Construction of PEI ‐EGFR‐PD‐L1‐siRNA dual functional nano‐vaccine and therapeutic efficacy evaluation for lung cancer
ConclusionOur constructed lipid nanoparticles of tumor targeted therapy gene siRNA combination had the ability to target cells in vitro and downregulate the expression of PD-L1, realizing the tumor-specific expression of immune-stimulating cytokines, which is a highly efficient and safe targeted therapy nano-vaccine.
Source: Thoracic Cancer - September 19, 2022 Category: Cancer & Oncology Authors: Guixue Yang, Dong Zhou, Yin Dai, Yanqi Li, Jiang Wu, Quanxing Liu, Xufeng Deng Tags: ORIGINAL ARTICLE Source Type: research

Directing the Way-Receptor and Chemical Targeting Strategies for Nucleic Acid Delivery
Pharm Res. 2022 Sep 15. doi: 10.1007/s11095-022-03385-w. Online ahead of print.ABSTRACTNucleic acid therapeutics have shown great potential for the treatment of numerous diseases, such as genetic disorders, cancer and infections. Moreover, they have been successfully used as vaccines during the COVID-19 pandemic. In order to unfold full therapeutical potential, these nano agents have to overcome several barriers. Therefore, directed transport to specific tissues and cell types remains a central challenge to receive carrier systems with enhanced efficiency and desired biodistribution profiles. Active targeting strategies in...
Source: Cell Research - September 15, 2022 Category: Cytology Authors: Ricarda Carolin Steffens Ernst Wagner Source Type: research

Directing the Way —Receptor and Chemical Targeting Strategies for Nucleic Acid Delivery
AbstractNucleic acid therapeutics have shown great potential for the treatment of numerous diseases, such as genetic disorders, cancer and infections. Moreover, they have been successfully used as vaccines during the COVID-19 pandemic. In order to unfold full therapeutical potential, these nano agents have to overcome several barriers. Therefore, directed transport to specific tissues and cell types remains a central challenge to receive carrier systems with enhanced efficiency and desired biodistribution profiles. Active targeting strategies include receptor-targeting, mediating cellular uptake based on ligand-receptor in...
Source: Pharmaceutical Research - September 15, 2022 Category: Drugs & Pharmacology Source Type: research

Exosomes carrying immune checkpoints, a promising therapeutic approach in cancer treatment
AbstractExosomes are a subgroup of extracellular vesicles generated by distinct cells. Tumor-derived extracellular vesicles convey immunological checkpoint molecules. TEXs as critical mediators in tumor development, metastasis, and immune escape have recently become the focus of scientific research. Exosomes are involved in the regulation of the immune system. Exosomes interact with target cells in the tumor microenvironment, changing their function based on the cargo they contain. Exosomal immune checkpoints might be exploited to track tumor immune evasion, treatment response, and patient prognosis while enhancing tumor c...
Source: Medical Oncology - September 7, 2022 Category: Cancer & Oncology Source Type: research

A lipid nanoparticle platform for mRNA delivery through repurposing of cationic amphiphilic drugs
J Control Release. 2022 Aug 10:S0168-3659(22)00514-4. doi: 10.1016/j.jconrel.2022.08.009. Online ahead of print.ABSTRACTSince the recent clinical approval of siRNA-based drugs and COVID-19 mRNA vaccines, the potential of RNA therapeutics for patient healthcare has become widely accepted. Lipid nanoparticles (LNPs) are currently the most advanced nanocarriers for RNA packaging and delivery. Nevertheless, the intracellular delivery efficiency of state-of-the-art LNPs remains relatively low and safety- and immunogenicity concerns with synthetic lipid components persist, altogether rationalizing the exploration of alternative ...
Source: Cancer Control - August 13, 2022 Category: Cancer & Oncology Authors: Bram Bogaert F élix Sauvage Roberta Guagliardo Cristina Muntean Van Phuc Nguyen Eline Pottie Mike Wels An-Katrien Minnaert Riet De Rycke Qiangbing Yang Dan Peer Niek Sanders Katrien Remaut Yannis M Paulus Christophe Stove Stefaan C De Smedt Koen Raemdonc Source Type: research

Expanding Biology of PCSK9: Roles in Atherosclerosis and Beyond
Curr Atheroscler Rep. 2022 Jul 29. doi: 10.1007/s11883-022-01057-z. Online ahead of print.ABSTRACTPURPOSE OF REVIEW: Since the discovery of PCSK9 in 2003, this proprotein convertase was shown to target specific receptors for degradation in endosomes/lysosomes, including LDLR and other family members and hence to enhance the levels of circulating LDL-cholesterol (LDLc). Accordingly, inhibitors of PCSK9, including monoclonal antibodies blocking its circulating activity and siRNA silencers of its hepatic expression, are now used in clinics worldwide to treat hypercholesterolemia patients effectively and safely in combination ...
Source: Atherosclerosis - July 29, 2022 Category: Cardiology Authors: Nabil G Seidah Damien Gar çon Source Type: research